ORTHOCELL LIMITED ORDINARY (OCC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
StockheadOrthocell records first sales of flagship nerve repair product Remplir in Canada
Orthocell records first sales of Remplir in Canada ... Read More The post Orthocell records first sales of flagship nerve repair product Remplir in Canada appeared first on Stockhead.
First Sales of Remplir Achieved in US$75m Canadian Market
other announcement
Orthocell’s nerve repair product Remplir posts near-90pc success rate as global rollout gains momentum
Data to support continued US expansion and planned European market entry, with approval targeted for H2 CY26 ... Read More The post Orthocell’s nerve repair product Remplir posts near-90pc success rate as global rollout gains momentum appeared first on Stockhead.
Compelling 90% Success Rate for Remplir in Real World Study
other announcement
Motley FoolOrthocell caps 26% surge this week with first US Military Surgery
The company's commercial rollout is off to a good start. The post Orthocell caps 26% surge this week with first US Military Surgery appeared first on The Motley Fool Australia.
KalkineIs Orthocell (ASX:OCC) Expanding Its Role in ASX All Ordinaries Biotech Sector?
Highlights Orthocell completes first Remplir procedure in US military hospital network. Healthcare sector activity reflects medical technology adoption and expansion. Market participation highlights integration of biotech companies within ASX indices. Orthocell completes a Remplir procedure in a US military hospital network, highlighting clinical deployment and biotechnology sector participation within ASX All Ordinaries. The healthcare and biotechnology sector represents a significant ...
First Surgical Use of Remplir in US Department of Defense
other announcement
Break it Down: Orthocell approved to sell Remplir to US defence hospital network
Orthocell gets Remplir approval across the US Department of Defence and Veterans Affairs hospital networks. ... Read More The post Break it Down: Orthocell approved to sell Remplir to US defence hospital network appeared first on Stockhead.
Health Check: Orthocell dons the fatigues with US defence deal
Orthocell shares have surged on the back of the nerve repair house gaining access to US military and veterans' hospitals. ... Read More The post Health Check: Orthocell dons the fatigues with US defence deal appeared first on Stockhead.
OCC Secures Access to 221 U.S. Military Medical Centres
other announcement
How Orthocell Limited (ASX:OCC) Fits in ASX 300 Healthcare Sector Trends
Highlights Orthocell prepares to release quarterly update and host investor webinar. Biotechnology operations reflect ongoing clinical and commercial activity. Healthcare sector participation continues across Australian equity indices. Orthocell prepares quarterly update and investor webinar, reflecting healthcare sector activity and biotechnology development within Australian equity markets. The healthcare and biotechnology sector remains a key contributor to Australian equity markets,...
US Section 232 Tariffs Not Expected to Affect Remplir
other announcement
Orthocell Investor Presentation - Broker Meets Biotech
other announcement
Orthocell Advances Global Reach with Remplir Success
Highlights Remplir used in real-world surgical settings Global expansion strategy gaining traction Strong financial base supports ongoing growth Orthocell’s Remplir device gains real-world validation through surgical use in demanding environments, strengthening its global expansion strategy and reinforcing its presence across medical and defence-related applications. Orthocell’s Remplir nerve repair device has taken a significant step forward, with its successful application...
Orthocell’s flagship nerve repair product Remplir used on injured soldiers in Ukraine
Orthocell’s Remplir used in 23 surgical procedures in Ukraine on soldiers who sustained nerve injuries during combat ... Read More The post Orthocell’s flagship nerve repair product Remplir used on injured soldiers in Ukraine appeared first on Stockhead.
Small CapsRemplir Used in 23 Surgeries in Ukrainian soldiers
other announcement
Orthocell Finalises Strategic Investment in Marine Biomedica
other announcement
Orthocell Posts Seventh Straight Record Revenue Quarter
earnings announcement
Orthocell Hits US Milestone - 100 Remplir Units Sold.
other announcement
Remplir Regulatory Application for US$750m EU-UK Market
other announcement
First Commercial Sales of Remplir Achieved in Hong Kong
other announcement
Remplir gains momentum in nerve-sparing prostate surgery
other announcement
2nd Distributor in Canada, Entire $75m Market Now Covered
other announcement
Remplir Launches in Hong Kong with First Surgical Case
other announcement
HK Distributor Signed as Remplir Expands in the Asian Market
other announcement